[go: up one dir, main page]

MX2015008104A - Uso de pidotimod para tratar la psoriasis. - Google Patents

Uso de pidotimod para tratar la psoriasis.

Info

Publication number
MX2015008104A
MX2015008104A MX2015008104A MX2015008104A MX2015008104A MX 2015008104 A MX2015008104 A MX 2015008104A MX 2015008104 A MX2015008104 A MX 2015008104A MX 2015008104 A MX2015008104 A MX 2015008104A MX 2015008104 A MX2015008104 A MX 2015008104A
Authority
MX
Mexico
Prior art keywords
pidotimod
treat psoriasis
acceptable salt
present
physiologically acceptable
Prior art date
Application number
MX2015008104A
Other languages
English (en)
Inventor
Federico Mailland
Maurizio Caserini
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MX2015008104A publication Critical patent/MX2015008104A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención está dirigida al uso de pidotimod, o una sal fisiológicamente aceptable del mismo, para tratar la psoriasis. Para el tratamiento de la presente invención, pidotimod, o una sal fisiológicamente aceptable del mismo, se puede administrar por vía sistémica o tópica.
MX2015008104A 2012-12-19 2012-12-19 Uso de pidotimod para tratar la psoriasis. MX2015008104A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/076088 WO2014094840A1 (en) 2012-12-19 2012-12-19 Use of pidotimod to treat psoriasis

Publications (1)

Publication Number Publication Date
MX2015008104A true MX2015008104A (es) 2015-11-06

Family

ID=47520054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008104A MX2015008104A (es) 2012-12-19 2012-12-19 Uso de pidotimod para tratar la psoriasis.

Country Status (31)

Country Link
US (1) US20150328191A1 (es)
EP (1) EP2934521B1 (es)
JP (1) JP6051315B2 (es)
KR (1) KR20150095773A (es)
CN (1) CN104869994B (es)
AR (1) AR094027A1 (es)
AU (1) AU2012396942A1 (es)
BR (1) BR112015011391A2 (es)
CA (1) CA2887878A1 (es)
CY (1) CY1118645T1 (es)
DK (1) DK2934521T3 (es)
EA (1) EA201591185A1 (es)
ES (1) ES2617235T3 (es)
HK (1) HK1210937A1 (es)
HR (1) HRP20161666T1 (es)
HU (1) HUE031846T2 (es)
IL (1) IL239429A0 (es)
LT (1) LT2934521T (es)
MA (1) MA38155B1 (es)
ME (1) ME02560B (es)
MX (1) MX2015008104A (es)
PH (1) PH12015501210A1 (es)
PL (1) PL2934521T3 (es)
PT (1) PT2934521T (es)
RS (1) RS55436B1 (es)
SG (1) SG11201503270UA (es)
SI (1) SI2934521T1 (es)
SM (2) SMT201700072T1 (es)
TN (1) TN2015000142A1 (es)
WO (1) WO2014094840A1 (es)
ZA (1) ZA201502573B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036009A1 (en) * 2013-09-10 2015-03-19 Polichem S.A. Pidotimod for use in the treatment of inflammation-associated diseases
MA44510A (fr) * 2016-03-29 2021-03-31 Janssen Biotech Inc Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
CN105943505A (zh) * 2016-05-26 2016-09-21 杭州百诚医药科技股份有限公司 一种匹多莫德药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO2003018011A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase

Also Published As

Publication number Publication date
ZA201502573B (en) 2016-11-30
PH12015501210A1 (en) 2015-08-17
ME02560B (me) 2017-02-20
AU2012396942A2 (en) 2015-07-30
MA38155B1 (fr) 2016-09-30
EP2934521A1 (en) 2015-10-28
SI2934521T1 (sl) 2017-03-31
EP2934521B1 (en) 2016-11-30
HUE031846T2 (hu) 2017-08-28
HK1210937A1 (en) 2016-05-13
SMT201700072T1 (it) 2017-03-08
CY1118645T1 (el) 2017-07-12
AU2012396942A1 (en) 2015-07-02
WO2014094840A1 (en) 2014-06-26
AR094027A1 (es) 2015-07-08
PT2934521T (pt) 2017-03-03
JP6051315B2 (ja) 2016-12-27
BR112015011391A2 (pt) 2017-07-11
CN104869994A (zh) 2015-08-26
CN104869994B (zh) 2016-10-12
SMT201700072B (it) 2017-03-08
CA2887878A1 (en) 2014-06-26
EA201591185A1 (ru) 2016-02-29
JP2016503043A (ja) 2016-02-01
LT2934521T (lt) 2016-12-27
HRP20161666T1 (hr) 2017-01-27
PL2934521T3 (pl) 2017-06-30
TN2015000142A1 (en) 2016-10-03
MA38155A1 (fr) 2016-02-29
SG11201503270UA (en) 2015-07-30
ES2617235T3 (es) 2017-06-15
RS55436B1 (sr) 2017-04-28
IL239429A0 (en) 2015-07-30
DK2934521T3 (en) 2017-02-06
US20150328191A1 (en) 2015-11-19
KR20150095773A (ko) 2015-08-21

Similar Documents

Publication Publication Date Title
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
NI201400083A (es) Compuesto de imidazopirrolidinona
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CR20140108A (es) Compuesto de ciclopropanoamina
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
UY35745A (es) Derivados sustituidos de fenilalanina
MX2015008104A (es) Uso de pidotimod para tratar la psoriasis.
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
MX2015008129A (es) Uso de pidotimod para tratar la dermatitis atopica.
DOP2016000062A (es) Derivados de indol-urea de glucopiranosil sustituido y su uso como inhibidores de sglt
PE20151159A1 (es) Uso de pidotimod para tratar la dermatitis atopica
CL2014003072A1 (es) Uso de un compuesto 2-((2r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida (veliparib o abt-888) o de una sal farmaceuticamente aceptable que sirve para el tratamiento de las metástasis en el cerebro con una combinación de una terapia con radiación en la totalidad del cerebro.
AR118704A2 (es) Polipéptido del factor vii para tratar enfermedades
AR095890A1 (es) Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia
MY177715A (en) Use of pidotimod to treat atopic dermatitis
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis